JP2010131022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010131022A5 JP2010131022A5 JP2010001962A JP2010001962A JP2010131022A5 JP 2010131022 A5 JP2010131022 A5 JP 2010131022A5 JP 2010001962 A JP2010001962 A JP 2010001962A JP 2010001962 A JP2010001962 A JP 2010001962A JP 2010131022 A5 JP2010131022 A5 JP 2010131022A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- prostate cancer
- diagnostic marker
- cancer antigen
- antigen diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 239
- 108020004707 nucleic acids Proteins 0.000 claims 233
- 102000039446 nucleic acids Human genes 0.000 claims 233
- 206010060862 Prostate cancer Diseases 0.000 claims 154
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 154
- 239000003550 marker Substances 0.000 claims 139
- 239000000427 antigen Substances 0.000 claims 138
- 102000036639 antigens Human genes 0.000 claims 138
- 108091007433 antigens Proteins 0.000 claims 138
- 108090000765 processed proteins & peptides Proteins 0.000 claims 69
- 229920001184 polypeptide Polymers 0.000 claims 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims 68
- 230000000295 complement effect Effects 0.000 claims 31
- 230000002255 enzymatic effect Effects 0.000 claims 30
- 238000000034 method Methods 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000000523 sample Substances 0.000 claims 23
- 241000124008 Mammalia Species 0.000 claims 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 20
- 108020004999 messenger RNA Proteins 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 16
- 239000002773 nucleotide Substances 0.000 claims 15
- 125000003729 nucleotide group Chemical group 0.000 claims 15
- 102000004190 Enzymes Human genes 0.000 claims 12
- 108090000790 Enzymes Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 10
- 230000001105 regulatory effect Effects 0.000 claims 8
- 230000000692 anti-sense effect Effects 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 241000282412 Homo Species 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 210000002307 prostate Anatomy 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 230000003197 catalytic effect Effects 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 229940104302 cytosine Drugs 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 101000573945 Coccidioides posadasii (strain C735) Neutral protease 2 homolog MEP2 Proteins 0.000 claims 2
- 102400001368 Epidermal growth factor Human genes 0.000 claims 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims 2
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 210000003567 ascitic fluid Anatomy 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 229940116977 epidermal growth factor Drugs 0.000 claims 2
- 239000005090 green fluorescent protein Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 210000003281 pleural cavity Anatomy 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/140,602 US7790861B2 (en) | 1999-09-24 | 2002-05-07 | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004502932A Division JP2006518182A (ja) | 2002-05-07 | 2003-05-07 | Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010131022A JP2010131022A (ja) | 2010-06-17 |
| JP2010131022A5 true JP2010131022A5 (cg-RX-API-DMAC7.html) | 2011-05-06 |
Family
ID=29418388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004502932A Withdrawn JP2006518182A (ja) | 2002-05-07 | 2003-05-07 | Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット |
| JP2010001962A Pending JP2010131022A (ja) | 2002-05-07 | 2010-01-07 | Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004502932A Withdrawn JP2006518182A (ja) | 2002-05-07 | 2003-05-07 | Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7790861B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1507787B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2006518182A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE534654T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003239357B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2484845A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2004133036A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003094844A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8440409B2 (en) * | 2005-09-19 | 2013-05-14 | The Johns Hopkins University | Protein C inhibitor as a biomarker for prostate cancer |
| JP2007222160A (ja) * | 2006-01-26 | 2007-09-06 | National Institute Of Advanced Industrial & Technology | 生体由来試料中の蛋白質の解析方法 |
| JP2010540534A (ja) | 2007-09-28 | 2010-12-24 | イントレキソン コーポレーション | 生体治療分子の発現のための治療遺伝子スイッチ構築物およびバイオリアクター、ならびにその使用 |
| CN101469348B (zh) * | 2008-08-29 | 2011-07-20 | 苏州福英基因科技有限公司 | 一种前列腺癌症早期的原位杂交检测试剂盒及其检测方法和应用 |
| JP6941565B2 (ja) | 2015-05-12 | 2021-09-29 | ドレクセル ユニバーシティ | がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法 |
| CN108659062B (zh) * | 2018-04-18 | 2021-06-22 | 中国农业科学院兰州畜牧与兽药研究所 | 唾液酸寡糖-磁纳米酶及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763209A (en) | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
| US5578444A (en) | 1991-06-27 | 1996-11-26 | Genelabs Technologies, Inc. | Sequence-directed DNA-binding molecules compositions and methods |
| US6066452A (en) | 1997-08-06 | 2000-05-23 | Yale University | Multiplex selection technique for identifying protein-binding sites and DNA-binding proteins |
| US20020042062A1 (en) * | 1999-09-24 | 2002-04-11 | Mark Stearns | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
| JP2003530077A (ja) * | 1999-09-24 | 2003-10-14 | フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン | Ｐｃａｍ−１マーカータンパク質、ｐｃａｍ−１をコードする核酸配列及びｐｃａｍ−１の検出のための免疫アッセイ |
| CA2399776A1 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| EP1599498A2 (en) * | 2003-03-03 | 2005-11-30 | Genentech, Inc. | Compositions and methods for the treatment of systemic lupus erythematosis |
-
2002
- 2002-05-07 US US10/140,602 patent/US7790861B2/en not_active Expired - Lifetime
-
2003
- 2003-05-05 RU RU2004133036/12A patent/RU2004133036A/ru not_active Application Discontinuation
- 2003-05-07 JP JP2004502932A patent/JP2006518182A/ja not_active Withdrawn
- 2003-05-07 AT AT03733941T patent/ATE534654T1/de active
- 2003-05-07 EP EP20030733941 patent/EP1507787B1/en not_active Expired - Lifetime
- 2003-05-07 WO PCT/US2003/014098 patent/WO2003094844A2/en not_active Ceased
- 2003-05-07 AU AU2003239357A patent/AU2003239357B2/en not_active Ceased
- 2003-05-07 CA CA 2484845 patent/CA2484845A1/en not_active Abandoned
-
2010
- 2010-01-07 JP JP2010001962A patent/JP2010131022A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023237051B2 (en) | Oligonucleotide probes and uses thereof | |
| AU2023226698A1 (en) | Oligonucleotide probes and uses thereof | |
| EP2890815B1 (en) | Methods for diagnosis and treatment of cancer | |
| CN107109494B (zh) | Il-33介导型疾病的治疗方法和诊断方法 | |
| US10705087B2 (en) | Detection method for NTRK3 fusion | |
| WO1999033963A1 (en) | Metastatic cancer regulated gene | |
| JP2009502115A5 (cg-RX-API-DMAC7.html) | ||
| WO2014017491A1 (ja) | Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子 | |
| US20110262464A1 (en) | Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3 | |
| JP2006517092A (ja) | 心不全遺伝子の決定及び治療薬スクリーニング | |
| JP2010131022A5 (cg-RX-API-DMAC7.html) | ||
| JP2014503180A5 (cg-RX-API-DMAC7.html) | ||
| JP6721189B2 (ja) | ｖＷＦに結合するＤＮＡアプタマー | |
| JP2011254830A (ja) | 結腸癌に関するポリヌクレオチド | |
| RU2013104137A (ru) | Изоформы bard1 при раке легкого и колоректальном раке и их применение | |
| CN112870362B (zh) | Circ-MET-1214和/或Circ-M50作为靶点在制备抗肿瘤药物中的用途 | |
| JP2010502192A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2017195809A1 (ja) | 炎症促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| WO2011112859A2 (en) | Methods relating to olanzapine pharmacogenetics | |
| CN101664550A (zh) | 治疗或预防癌症的方法和药物 | |
| CA2634488A1 (en) | Catecholamine regulated protein | |
| KR102025005B1 (ko) | 전암성 병변에서 조기 간암을 진단 및 예측할 수 있는 바이오 마커 및 이의용도 | |
| JP6731254B2 (ja) | 新規融合体及びその検出法 | |
| KR102270926B1 (ko) | Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물 | |
| EP4454663A1 (en) | Therapeutic or prophylactic agent for heart attack, heart fibrosis, or heart failure, where htra3 is therapeutic target |